Impact of P53 and SIRT1 in Type 2 Diabetes
ConditionDM
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorSherief Abd-Elsalam
About this trial
Investigating the impact of p53 and SIRT1 in the development of type 2 DM
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Prediabetic subjects.
Disqualifiers
Confirmed diabetes.
Hepatic or renal impairment.
Trial design
Design model
Parallel
Treatments tested in this trial
life style
Other interventionlife sryle control only
Metformin
Drugmetformin twice daily
Nigetella salivata
DrugNS twice daily
Treatment groups
90 Participants
are divided into 3 treatment groupsGroup A: life styleOther 1 intervention
Group B: MetforminActive comparator 1 intervention
Group C: Nigetella salivataExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Number of patients with improved insulin resistance
Number of patients showing improved insulin resistance
Time frame
6 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Sherief Abd-Elsalam
Lead sponsor
Tanta University
Sponsor institution
Source ClinicalTrials.gov